PD1-PDL1 inhibitor 2 is a inhibitor of the PD-1 (Programmed death- 1) /PD-L1 (Programmed death-ligand 1) protein/protein interaction. BMS-202 binds to and induces dimerization of PD-L1, an inhibitory immune checkpoint protein. Blockade of the PD-1/PD-Ll ligation using antibodies to PD-Ll has been shown to restore and augment T cell activation in many systems.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 40 mg/mL|
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM, et al. Structure. 2017 Aug 1;25(8):1163-1174. PMID: 28768162.
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM, et al. Oncotarget. 2016 May 24;7(21):30323-35. PMID: 27083005.
|Related PD-1/PD-L1 Products|
|PD1-PDL1 inhibitor 1
PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM.
Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.